Evidence map›Paper›PMID 28112226›Full record

ArticleScientific reports2017

Click-Chemistry Based High Throughput Screening Platform for Modulators of Ras Palmitoylation.

Lakshmi Ganesan, Peyton Shieh, Carolyn R Bertozzi, Ilya Levental

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Insights into auto-RSC chemical biology · 2021
    Review
  5. Inhibitors of DHHC family proteins.Current opinion in chemical biology · 2021
    Review
  6. Review
  7. Regulation of Dynamic Protein S-Acylation.Frontiers in molecular biosciences · 2021
    Review
  8. Article
  9. Review
  10. cat-ELCCA: catalyzing drug discovery through click chemistry.Chemical communications (Cambridge, England) · 2018
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lakshmi GanesanDepartment of Integrated Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Peyton ShiehDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Carolyn R BertozziDepartment of Chemistry, Stanford University, Stanford, CA 94305, USA.
Ilya LeventalDepartment of Integrated Biology and Pharmacology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Funding

Univ of Calif Berkeley Chemistry-Biology Interface ProgramT32GM066698 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI CHANG, CHRISTOPHER J., FRANCIS, MATTHEW B · 2004 to 2023
$7.5M
Mycobacterial Sulfation PathwaysR01AI051622 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 2002 to 2015
$6.0M
Metabolic Engineering with Bioorthogonal Chemical ReportersR37GM058867 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI BERTOZZI, CAROLYN · 2009 to 2018
$4.7M
Lipidomic, biophysical, and functional differentiation of Mesenchymal Stem Cell membranesR01GM114282 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LEVENTAL, ILYA · 2015 to 2019
$1.7M
NIAID NIH HHS R01 AI051622NIGMS NIH HHS R01 GM114282NIGMS NIH HHS R37 GM058867NIGMS NIH HHS T32 GM066698
6 · The paper itself

Abstract

Palmitoylation is a widespread, reversible lipid modification that has been implicated in regulating a variety of cellular processes. Approximately one thousand proteins are annotated as being palmitoylated, and for some of these, including several oncogenes of the Ras and Src families, palmitoylation is indispensable for protein function. Despite this wealth of disease-relevant targets, there are currently few effective pharmacological tools to interfere with protein palmitoylation. One reason for this lack of development is the dearth of assays to efficiently screen for small molecular inhibitors of palmitoylation. To address this shortcoming, we have developed a robust, high-throughput compatible, click chemistry-based approach to identify small molecules that interfere with the palmitoylation of Ras, a high value therapeutic target that is mutated in up to a third of human cancers. This assay design shows excellent performance in 384-well format and is sensitive to known, non-specific palmitoylation inhibitors. Further, we demonstrate an ideal counter-screening strategy, which relies on a target peptide from an unrelated protein, the Src-family kinase Fyn. The screening approach described here provides an integrated platform to identify specific modulators of palmitoylated proteins, demonstrated here for Ras and Fyn, but potentially applicable to pharmaceutical targets involved in a variety of human diseases.

Indexed as

LipoylationClick ChemistryDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysProto-Oncogene Proteins c-fynras ProteinsProto-Oncogene Proteins c-fynras Proteins

Identifiers

PMID28112226
PMCPMC5255568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.